A 16-Day, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Trial Comparing Lumiracoxib 100mg o.d. With Naproxen 500 mg b.i.d. Plus Omeprazole 20mg o.d. and Placebo in Healthy Volunteers to Investigate on the Safety and Tolerability of Lumiracoxib in the Small Bowel.
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Lumiracoxib; Omeprazole/naproxen
- Indications Arthritis; Musculoskeletal pain; NSAID-induced gastrointestinal damage
- Focus Adverse reactions
- Sponsors Novartis
- 12 Dec 2007 Status changed from in progress to completed.
- 29 Oct 2006 New trial record.